Rhythm Pharmaceuticals (RYTM) announced a proposed public offering of $150M of its common stock. All securities in the offering will be offered by Rhythm. Morgan Stanley, BofA Securities, Stifel and Wells Fargo Securities are acting as joint book-running managers for the proposed offering. Canaccord Genuity and Citizens Capital Markets are acting as lead managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals price target raised to $95 from $72 at Needham
- Rhythm Pharmaceuticals price target raised to $95 from $73 at BofA
- Rhythm Pharmaceuticals price target raised to $95 from $80 at Morgan Stanley
- Rhythm Pharmaceuticals price target raised to $123 from $94 at Stifel
- Rhythm Pharmaceuticals price target raised to $129 from $91 at Wells Fargo